Dpb Pharmaceuticals Limited - Due diligence report

A 360° intelligence report on Dpb Pharmaceuticals Limited: trust score, financial health, credit view, compliance, directors, growth and dis…

2018-04-20 Mumbai, Maharashtra Active Unlisted
Share
Connect MCP
DP Dpb Pharmaceuticals Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Dpb Pharmaceuticals Limited — 360° Intelligence Report

Generated from MCA filings & public records
84/100
Trust Score
Low Risk

Dpb Pharmaceuticals Limited is assessed as Low Risk with a Trust Score of 84/100. Dpb Pharmaceuticals Limited is an active public limited indian non-government company incorporated in 2018, operating in the Pharma sector. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 03 Aug 2026 from the latest processed filings. Dpb Pharmaceuticals Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
84/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
73/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
70/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 70/100 Moderate
  • Open charges exceed net worth - secured lenders rank ahead.
  • Moderate gearing (D/E 38%).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 4 open (74.00 cr) · 1 satisfied (10.00 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others2 48.0 cr
Yes Bank Limited1 48.0 cr
Hdfc Bank Limited1 48.0 cr
The Hongkong And Shanghai Banking Corporation Limited1 48.0 cr
Compliance Score: 73/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 1 court forum(s).
  • Delayed payments to MSME suppliers disclosed (109 disclosure(s)).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
DEVANG MANHARLAL AJMERA 01234567 Director 01/04/2018 6 yrs Approved
PIYUSH MANHARLAL AJMERA 01234567 Director 01/04/2018 6 yrs Approved
BHAVIN MANHARLAL AJMERA 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2021)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
2
Capital events
1 allotment(s) · 2 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Dpb Antibiotics Private Limited Associate Company 74.00%
Cosmic Drugs And Chemical Private Limited Associate Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 65 · Distress 80
Growth signals & trust indicators
Latest year revenue grew 1.42.
Asset base grew 2.1x - capacity expansion.
Operating for 8 years.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 24% in a year.
4 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 22.36 cr.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence78/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment78/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 4 open charge(s) of 74.00 cr already registered.
  • Compliance record supports lending.
Investor view80/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 14 events
24 Sep 2025
Charge satisfied
Hdfc Bank Limited
02 Apr 2025
Charge created
Others - 24.00 cr
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
26 Mar 2024
Charge created
Yes Bank Limited - 20.00 cr
31 Mar 2023
Share transfer (FY 2023)
51350.00000000 shares to Ajmera Manaharlal Bhavin
19 Aug 2022
Charge created
Hdfc Bank Limited - 10.00 cr
24 Jun 2022
Charge created
Others - 20.00 cr
26 Apr 2022
Charge created
The Hongkong And Shanghai Banking Corporation Limited - 10.00 cr
08 Oct 2021
Securities allotted
3081000 Equity Shares - 3.08 cr raised
20 Apr 2018
Incorporated
Registered with Roc Mumbai I
Director appointed
DEVANG MANHARLAL AJMERA (Director)
Director appointed
PIYUSH MANHARLAL AJMERA (Director)
Director appointed
BHAVIN MANHARLAL AJMERA (Director)
10

Key Observations

Auto-generated from the data above
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Transcoal Impex Private Limited U74999KA2016PTC093076 Bangalore North, Karnataka, India
Milklane U52101MH2015PTC269084 Mumbai, Maharashtra, India
Gugnani Autocars Private Limited U74999OR2018PTC028159 Bhubaneswar, Orissa, India
Prabhat Cables U40100MH2010PTC201578 Mumbai, Maharashtra, India
Aadesh Enterprises Private Limited U70100MH2000PTC125552 Mumbai, Maharashtra, India
Star India Agencies U74900WB2011PTC158251 Kolkata, West Bengal, India
Ceragon Networks U51909DL2003PTC118490 New Delhi, Delhi, India
Annu Polychem Private Limited U74899DL1983PTC014929 Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Dpb Pharmaceuticals Limited before audits and certifications: compliance score 73/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Dpb Pharmaceuticals Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 70/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 65/100, margin trends, ownership structure and peer set for Dpb Pharmaceuticals Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 84/100, distress signals and MSME payment-delay disclosures - know whether Dpb Pharmaceuticals Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Dpb Pharmaceuticals Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Dpb Pharmaceuticals Limited an active company?

Dpb Pharmaceuticals Limited has MCA status “Active” with a compliance score of 73/100 (Moderate).

Is Dpb Pharmaceuticals Limited financially healthy?

Dpb Pharmaceuticals Limited has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Dpb Pharmaceuticals Limited?

Its overall Trust Score is 84/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Dpb Pharmaceuticals Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Dpb Pharmaceuticals Limited have loans or charges against its assets?

4 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.

Is Dpb Pharmaceuticals Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 73/100 (Moderate).

Is it risky to lend to Dpb Pharmaceuticals Limited?

Its Credit Risk Score is 70/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.